These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 20447065)

  • 1. d3-Growth hormone receptor polymorphism in acromegaly: effects on metabolic phenotype.
    Montefusco L; Filopanti M; Ronchi CL; Olgiati L; La-Porta C; Losa M; Epaminonda P; Coletti F; Beck-Peccoz P; Spada A; Lania AG; Arosio M
    Clin Endocrinol (Oxf); 2010 May; 72(5):661-7. PubMed ID: 20447065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homozygosity of the d3-growth hormone receptor polymorphism is associated with a high total effect of GH on growth and a low BMI in girls with Turner syndrome.
    Binder G; Trebar B; Baur F; Schweizer R; Ranke MB
    Clin Endocrinol (Oxf); 2008 Apr; 68(4):567-72. PubMed ID: 17973940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and biochemical impact of the d3 growth hormone receptor genotype in acromegaly.
    Mercado M; González B; Sandoval C; Esquenazi Y; Mier F; Vargas G; de los Monteros AL; Sosa E
    J Clin Endocrinol Metab; 2008 Sep; 93(9):3411-5. PubMed ID: 18611972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of the exon 3 deleted/full-length GHR polymorphism with recombinant growth hormone dose in growth hormone-deficient adults.
    Meyer S; Schaefer S; Stolk L; Arp P; Uitterlinden AG; Plöckinger U; Stalla GK; Tuschy U; Weber MM; Weise A; Pfützner A; Kann PH
    Pharmacogenomics; 2009 Oct; 10(10):1599-608. PubMed ID: 19842933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GHR exon 3 polymorphism: association with type 2 diabetes mellitus and metabolic disorder.
    Strawbridge RJ; Kärvestedt L; Li C; Efendic S; Ostenson CG; Gu HF; Brismar K
    Growth Horm IGF Res; 2007 Oct; 17(5):392-8. PubMed ID: 17537658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly.
    Bianchi A; Giustina A; Cimino V; Pola R; Angelini F; Pontecorvi A; De Marinis L
    J Clin Endocrinol Metab; 2009 Jun; 94(6):2015-22. PubMed ID: 19336510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The growth hormone receptor polymorphism in patients with acromegaly: relationship to BMI and glucose metabolism.
    Turgut S; Akın F; Ayada C; Topsakal S; Yerlikaya E; Turgut G
    Pituitary; 2012 Sep; 15(3):374-9. PubMed ID: 21744231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone (GH) receptor isoform in acromegaly: lower concentrations of GH but not insulin-like growth factor-1 in patients with a genomic deletion of exon 3 in the GH receptor gene.
    Schmid C; Krayenbuehl PA; Bernays RL; Zwimpfer C; Maly FE; Wiesli P
    Clin Chem; 2007 Aug; 53(8):1484-8. PubMed ID: 17573420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone receptor exon 3 isoforms may have no importance in the clinical setting of multiethnic Brazilian acromegaly patients.
    de Oliveira Machado E; Lima CH; Ogino LL; Kasuki L; Gadelha MR
    Pituitary; 2016 Aug; 19(4):375-80. PubMed ID: 27001494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring for potential residual disease activity by serum insulin-like growth factor 1 and soluble Klotho in patients with acromegaly after pituitary surgery: is there an impact of the genomic deletion of exon 3 in the growth hormone receptor (d3-GHR) gene on "safe" GH cut-off values?
    Kohler S; Tschopp O; Sze L; Neidert M; Bernays RL; Spanaus KS; Wiesli P; Schmid C
    Gen Comp Endocrinol; 2013 Jul; 188():282-7. PubMed ID: 23648743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid and high throughput genotyping of the growth hormone receptor exon 3 deleted/full-length polymorphism using a tagSNP.
    Glad CA; Johannsson G; Carlsson LM; Svensson PA
    Growth Horm IGF Res; 2010 Jun; 20(3):270-3. PubMed ID: 20219401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exon 3-deleted and full-length growth hormone receptor polymorphism frequencies in an Iranian population.
    Palizban AA; Radmansorry M; Bozorgzad M
    Res Pharm Sci; 2014; 9(6):489-94. PubMed ID: 26339263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of the d3GH receptor polymorphism on the metabolic and biochemical phenotype of GH-deficient adults at baseline and during short- and long-term recombinant human GH replacement therapy.
    Giavoli C; Ferrante E; Profka E; Olgiati L; Bergamaschi S; Ronchi CL; Verrua E; Filopanti M; Passeri E; Montefusco L; Lania AG; Corbetta S; Arosio M; Ambrosi B; Spada A; Beck-Peccoz P
    Eur J Endocrinol; 2010 Sep; 163(3):361-8. PubMed ID: 20592127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The exon-3 deleted growth hormone receptor polymorphism predisposes to long-term complications of acromegaly.
    Wassenaar MJ; Biermasz NR; Pereira AM; van der Klaauw AA; Smit JW; Roelfsema F; van der Straaten T; Cazemier M; Hommes DW; Kroon HM; Kloppenburg M; Guchelaar HJ; Romijn JA
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4671-8. PubMed ID: 19864451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exon 3-deleted genotype of growth hormone receptor (GHRd3) positively influences IGF-1 increase at generation test in children with idiopathic short stature.
    Toyoshima MT; Castroneves LA; Costalonga EF; Mendonca BB; Arnhold IJ; Jorge AA
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):500-4. PubMed ID: 17555512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The exon 3-deleted/full-length growth hormone receptor polymorphism and response to growth hormone therapy in growth hormone deficiency and Turner syndrome: a multicenter study.
    Baş F; Darendeliler F; Aycan Z; Çetinkaya E; Berberoğlu M; Sıklar Z; Öcal G; Timirci Ö; Çetinkaya S; Darcan Ş; Gökşen Şimşek D; Bideci A; Cinaz P; Böber E; Demir K; Bereket A; Turan S; Atabek ME; Tütüncüler F; Isbir T; Bozkurt N; Kabataş Eryılmaz S; Uzunhan O; Küçükemre Aydın B; Bundak R
    Horm Res Paediatr; 2012; 77(2):85-93. PubMed ID: 22456308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between nocturnal growth hormone concentrations, serum IGF-I/IGFBP-3 levels, insulin sensitivity and GH receptor allelic variant in small for gestational age children.
    Mericq V; Román R; Iñiguez G; Angel B; Salazar T; Avila A; Perez-Bravo F; Cassorla F
    Horm Res; 2007; 68(3):132-8. PubMed ID: 17347571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D3 GH receptor polymorphism is not associated with IGF1 levels in untreated acromegaly.
    Kamenicky P; Dos Santos C; Espinosa C; Salenave S; Galland F; Le Bouc Y; Maison P; Bougnères P; Chanson P
    Eur J Endocrinol; 2009 Aug; 161(2):231-5. PubMed ID: 19439509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical and cardiometabolic effects of d3-growth hormone receptor polymorphism in acromegaly.
    Cinar N; Dagdelen S; Yorgun H; Canpolat U; Kabakçı G; Erbas T
    Pituitary; 2015 Feb; 18(1):116-25. PubMed ID: 24706164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The exon 3-deleted/full-length growth hormone receptor polymorphism does not influence the effect of puberty or growth hormone therapy on glucose homeostasis in short non-growth hormone-deficient small-for-gestational-age children: results from a two-year controlled prospective study.
    Audí L; Carrascosa A; Esteban C; Fernández-Cancio M; Andaluz P; Yeste D; Espadero R; Granada ML; Wollmann H; Fryklund L;
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2709-15. PubMed ID: 18445665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.